Oncolytic herpes simplex virus vectors for cancer virotherapy (Q28202611)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

review article

1 reference

title

Oncolytic herpes simplex virus vectors for cancer virotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

author name string

Susan Varghese

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

language of work or name

English

0 references

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

967-978

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

16 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

1 reference

7 January 2021

Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The Pathogenicity of Ribonucleotide Reductase-Null Mutants of Herpes Simplex Virus Type 1 in Mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Physical location of a herpes simplex virus type-1 gene function(s) specifically associated with a 10 million-fold increase in HSV neurovirulence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Prodrug-activating systems in suicide gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Replicative adenoviruses for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

The current status of clinical gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Targeting gene expression using HSV vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

1 reference

7 January 2021

Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700537

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700537

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12522436%20AND%20SRC:MED&resulttype=core&format=json

release_qiej2s6ewjhnpn6zrnaiw6cqdy

16 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qiej2s6ewjhnpn6zrnaiw6cqdy

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017